ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PFE Pfizer Inc

27.77
-0.01 (-0.04%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Pfizer Inc NYSE:PFE NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.04% 27.77 28.12 27.72 27.83 42,862,116 23:59:59

Pfizer: EMA Accepts Application for 20-Valent Pneumococcal Conjugate Vaccine

26/02/2021 1:10pm

Dow Jones News


Pfizer (NYSE:PFE)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Pfizer Charts.

By Colin Kellaher

 

Pfizer Inc. Friday said the European Medicines Agency accepted for review the drugmaker's marketing authorization application for its 20-valent pneumococcal conjugate vaccine candidate for adults ages 18 and older.

The New York company said the acceptance starts the formal review process by the agency's Committee for Medicinal Products for Human Use.

Pfizer's 20-valent vaccine candidate covers 13 serotypes already included in its Prevnar 13 vaccine, plus seven new serotypes. The company noted that the 20 serotypes are responsible for the majority of currently circulating pneumococcal disease worldwide.

The U.S. Food and Drug Administration in December granted priority review to Pfizer's application for the vaccine in adults, with a target action date in June.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

February 26, 2021 07:55 ET (12:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Pfizer Chart

1 Year Pfizer Chart

1 Month Pfizer Chart

1 Month Pfizer Chart

Your Recent History

Delayed Upgrade Clock